香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） 須予披露交易 進一步認購金融產品 進一步認購金融產品 董 事 會 謹 此 公 佈，於2026年3月16日（交 易 時 間 後），本 集 團 成 員 公 司 透 過 中 信 證券及其附屬公司認購該等中信證券金融產品且於本公告日期仍未到期的 該等中信證券金融產品合計投資總額為人民幣460,000,000元。 於 本 公 告 日 期，董 事 確 認：(i)除該等中信證券金融產品及首項中信證券金融 產 品（定 義 見 日 期 為2025年4月14日 的 公 告）仍 未 到 期 外，其 餘 的 所 有 向 中 信 證券認購（披 露 於 日 期 ...

Group 1 - The core viewpoint of the article highlights the strong performance of Hong Kong pharmaceutical stocks on March 6, with specific companies showing notable gains [1][2] Group 2 - Zhaoyan New Drug (06127.HK) increased by 3.60% [1] - Weiya Biotechnology (01873.HK) rose by 2.87% [1] - King’s Ray Bio (01548.HK) saw a gain of 1.75% [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 截至月份: 2026年2月28日 狀態: 新提交 公司名稱: 北京昭衍新藥研究中心股份有限公司 呈交日期: 2026年3月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06127 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 118,995,206 | RMB | | 1 | RMB | | 118,995,206 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 118,995,206 | RMB | | 1 | RMB | | 118,995,206 | | 2. 股份分類 ...

截至月份: 2026年2月28日 狀態: 新提交 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: 北京昭衍新藥研究中心股份有限公司 呈交日期: 2026年3月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06127 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 118,995,206 | RMB | | 1 | RMB | | 118,995,206 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 118,995,206 | RMB | | 1 | RMB | | 118,995,206 | | 2. 股份分類 ...

Core Viewpoint - The company expects a significant increase in net profit for 2025, while revenue is projected to decline, influenced by rising prices of laboratory monkeys and ongoing share reduction plans by major shareholders [1][2]. Financial Performance - The company forecasts a net profit attributable to shareholders between 233 million to 349 million yuan for 2025, representing a year-on-year increase of 214% to 371%. However, revenue is expected to decline by 13.9% to 22.1% year-on-year. The profit increase is primarily driven by the appreciation of biological assets, such as laboratory monkeys, while the contribution from laboratory service business profits is decreasing [2]. Management Changes - The actual controllers of the company, Feng Yuxia and Zhou Zhiwen, received regulatory warnings in 2024 for failing to timely disclose shareholding changes, and recent share reduction activities are ongoing. The share reduction plan is not yet completed as of January 2026, which may impact the company's equity structure [3]. Financial Condition - The market price of laboratory monkeys significantly increased in the second half of 2025, with prices ranging from 100,000 to 150,000 yuan per monkey, directly boosting the fair value of the company's biological assets. Analysts from Huatai Securities indicate that supply-demand gaps may lead to continued price increases over the next 2 to 3 years, which will affect the company's profit volatility [4]. Project Progress - The company's laboratory facility in Guangzhou has entered the completion acceptance stage, while the Suzhou facility passed CMA certification in July 2025. The commissioning of new bases may enhance service capacity, but attention is needed on order conversion efficiency [5]. Policy and Regulation - The U.S. Biodefense Act, included in the 2026 National Defense Authorization Act, has a five-year buffer period, which limits short-term impacts on Chinese CXO companies. However, long-term geopolitical risks still need to be monitored [6].

Group 1 - The Hong Kong pharmaceutical outsourcing sector experienced a strong rally on February 10, with several companies seeing significant stock price increases [1] - Zhaoyan New Drug (06127.HK), WuXi Biologics (02269.HK), and Via Biotechnology (01873.HK) all rose by over 3% [1] - Tigermed (03347.HK), WuXi AppTec (02359.HK), and Kelun Pharmaceutical (06821.HK) each saw their stock prices increase by more than 2.5% [1]

Group 1 - The Hong Kong pharmaceutical outsourcing sector has shown strong fluctuations, with companies such as Zhaoyan New Drug (06127.HK), WuXi Biologics (02269.HK), and Via Biotechnology (01873.HK) all rising over 3% [1] - Other companies like Tigermed (03347.HK), WuXi AppTec (02359.HK), and Kelun Pharmaceutical (06821.HK) have also experienced increases of more than 2.5% [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 第 1 頁 共 11 頁 v 1.2.0 致：香港交易及結算所有限公司 公司名稱: 北京昭衍新藥研究中心股份有限公司 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06127 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 118,995,206 | RMB | | 1 RMB | | 118,995,206 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 118,995,206 | RMB | | 1 RMB | | 118,995,206 | | 2. 股份 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京昭衍新藥研究中心股份有限公司 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06127 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 118,995,206 | RMB | | 1 RMB | | 118,995,206 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 118,995,206 | RMB | | 1 RMB | | 118,995,206 | | 2. 股份分類 | 普通股 | 股份類別 | A | ...

Group 1 - The core point of the news is that Zhaoyan New Drug's stock price increased by 5.08% to 37.68 CNY per share, with a trading volume of 424 million CNY and a turnover rate of 1.81%, resulting in a total market capitalization of 28.235 billion CNY [1] - Zhaoyan New Drug Research Center Co., Ltd. specializes in non-clinical safety evaluation services for drugs, with its main business revenue composition being 95.59% from non-clinical research services, 4.34% from clinical services, and 0.07% from experimental model supply [1] - The company was established on February 25, 1998, and went public on August 25, 2017, located in Beijing Economic and Technological Development Zone [1] Group 2 - Among the top ten circulating shareholders of Zhaoyan New Drug, Huabao Fund's Huabao CSI Medical ETF (512170) reduced its holdings by 2.1693 million shares in the third quarter, now holding 12.4838 million shares, which accounts for 1.67% of the circulating shares [2] - The estimated floating profit from Huabao CSI Medical ETF's investment in Zhaoyan New Drug is approximately 22.7206 million CNY [2] - Huabao CSI Medical ETF was established on May 20, 2019, with a current scale of 25.263 billion CNY, yielding 2.53% this year and 12.04% over the past year [2]